Taurolidine Antiadhesive Properties on Interaction with E. coli; Its Transformation in Biological Environment and Interaction with Bacteria Cell Wall
暂无分享,去创建一个
[1] M. Sezik,et al. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. , 2008, The Journal of surgical research.
[2] Stephan Rogalla,et al. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. , 2007, The Journal of surgical research.
[3] G. Kristiansen,et al. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy. , 2007, The Journal of surgical research.
[4] C. Braumann,et al. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case , 2006, World journal of surgical oncology.
[5] W. Hennink,et al. Identification of formaldehyde-induced modifications in proteins: reactions with insulin. , 2006, Bioconjugate chemistry.
[6] L. Nici,et al. The Effects of Taurolidine, a Novel Antineoplastic Agent, on Human Malignant Mesothelioma , 2004, Clinical Cancer Research.
[7] M Koldehoff,et al. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. , 2004, International journal of antimicrobial agents.
[8] S. Hensen,et al. Conservation of deduced amino acid sequence of FimH among Escherichia coli of bovine, porcine and avian disease origin. , 2004, Veterinary microbiology.
[9] D. Chatterjee,et al. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer , 2004, Cancer Chemotherapy and Pharmacology.
[10] M. Brock,et al. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. , 2004, Anticancer research.
[11] W. Hennink,et al. Identification of Formaldehyde-induced Modifications in Proteins , 2004, Journal of Biological Chemistry.
[12] H. Oğuz,et al. Intravitreal taurolidine against experimental Staphylococcus epidermidis endophthalmitis in rabbits , 2004, Current eye research.
[13] C. Braumann,et al. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy , 2004, Clinical & Experimental Metastasis.
[14] H. Guski,et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer , 2004, Clinical & Experimental Metastasis.
[15] Charles L. Brooks,et al. Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..
[16] H. Lukoff,et al. The effect of Taurolidine on adherent and floating subpopulations of melanoma cells , 2003, Anti-cancer drugs.
[17] G. Waksman,et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection , 2002, Molecular microbiology.
[18] M. Brock,et al. The effect of taurolidine on brain tumor cells. , 2002, Anticancer Research.
[19] H. Redmond,et al. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. , 2001, The Journal of surgical research.
[20] P. Calabresi,et al. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. , 2001, Cancer research.
[21] B. Delley. From molecules to solids with the DMol3 approach , 2000 .
[22] G. Eliopoulos,et al. Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis , 2000, Antimicrobial Agents and Chemotherapy.
[23] R. Sabat,et al. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. , 1997, American journal of surgery.
[24] Bernard Delley,et al. FAST CALCULATION OF ELECTROSTATICS IN CRYSTALS AND LARGE MOLECULES , 1996 .
[25] P. Tullio,et al. 2,4,7‐Trimethyl‐2,3‐dihydro‐4H‐pyrido[4,3‐e]‐1,2,4‐thiadiazinium 1,1‐Dioxide Iodide , 1995 .
[26] M. I. Halliday,et al. Enteral and parenteral anti-endotoxin treatment in experimental colitis. , 1994, Hepato-gastroenterology.
[27] R. Spagna,et al. PAUTO– an automatic procedure for crystal structure solution by the Patterson method in the CAOS package , 1994 .
[28] W. Traub,et al. Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. , 1993, Chemotherapy.
[29] K. Sikora,et al. Tumour inoculation during laparoscopy , 1993, The Lancet.
[30] Katsuo,et al. A System of Computer Programs for the Automatic Solution of Co ' sial Structures from X-ray Diffraction Data , 1993 .
[31] Jackson,et al. Atoms, molecules, solids, and surfaces: Applications of the generalized gradient approximation for exchange and correlation. , 1992, Physical review. B, Condensed matter.
[32] R. Endres,et al. Glycerol-induced unraveling of the tight helical conformation of Escherichia coli type 1 fimbriae , 1992, Journal of bacteriology.
[33] R. Endres,et al. Fragmentation of Escherichia coli type 1 fimbriae exposes cryptic D-mannose-binding sites , 1991, Journal of bacteriology.
[34] K. Krogfelt,et al. Direct evidence that the FimH protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae , 1990, Infection and immunity.
[35] B. Delley. An all‐electron numerical method for solving the local density functional for polyatomic molecules , 1990 .
[36] E. Beachey,et al. Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae , 1988, Nature.
[37] G. Thatcher,et al. Stereoelectronic effects in sulfate diesters and sulfuric acid , 1988 .
[38] S. Hull,et al. Attachment of Escherichia coli via mannose- or Gal alpha 1----4Gal beta-containing receptors to human colonic epithelial cells , 1988, Infection and immunity.
[39] A. Becke,et al. Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.
[40] E. Beachey,et al. Identification of two ancillary subunits of Escherichia coli type 1 fimbriae by using antibodies against synthetic oligopeptides of fim gene products , 1987, Journal of bacteriology.
[41] S. Gorman,et al. Electron and light microscopic observations of bacterial cell surface effects due to taurolidine treatment , 1987 .
[42] S. Gorman,et al. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. , 1987, The Journal of applied bacteriology.
[43] L. Maurer,et al. Receptor-binding function of type 1 pili effects bladder colonization by a clinical isolate of Escherichia coli , 1986, Infection and immunity.
[44] M. Gidley,et al. The mode of antibacterial action of some ‘masked’ formaldehyde compounds , 1981, FEBS letters.
[45] D. Schalch,et al. Identification of a somatomedin‐binding protein produced by a rat hepatoma cell line , 1981, FEBS letters.
[46] L. Hagberg,et al. Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections , 1981, Infection and immunity.
[47] M. Martí,et al. [Intraperitoneal and intravenous tauroflex, without antibiotics in the treatment of 40 cases of peritonitis (author's transl)]. , 1978, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.
[48] J. L. Lawrence,et al. The refinement of the crystal structure of a-rhamnose monohydrate , 1971 .